{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-26-000039","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.062220+00:00","generated_at":"2026-05-15T14:53:53.641776+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pliant Therapeutics reports Q4 2025 net loss of $23.6M; advances PLN-101095 Phase 1b after positive ICI-refractory data","bullets":["PLN-101095 Phase 1: 4 responders (1 CR, 3 PR) out of 10 secondary ICI-refractory patients; IFN-γ biomarker correlated with response.","Accelerated development: Phase 1b indication expansion trial initiated for NSCLC, RCC, high TMB; first patient enrollment expected Q2 2026.","Q4 2025 net loss $23.6M vs $49.7M YoY; R&D expense fell to $15.6M from $38.8M due to BEACON-IPF discontinuation.","Cash, equivalents and short-term investments $192.4M; expected to fund operations into second half 2028.","Appointed Minnie Kuo as COO; INTEGRIS-PSC Phase 2 results published in Journal of Hepatology (Jan 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-26-000039","json":"https://secwatch.observer/filing/0001746473-26-000039.json","markdown":"https://secwatch.observer/filing/0001746473-26-000039.md","text":"https://secwatch.observer/filing/0001746473-26-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/0001746473-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/plrx-20260311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:53:53.641776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3342fec78086d2dfeb1b88e351dade61c381ea53","claim":"PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income $23.6 million.","evidence_excerpt":"Net loss was $23.6 million as compared to $49.7 million for the prior-year quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/0001746473-26-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2025"},{"label":"Net income","value":"$23.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}